(Q45108563)

9 December 2017

title

Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors (English)

1 reference

9 December 2017

main subject

angiogenesis inhibitor

1 reference

1

1 reference

9 December 2017

9

Jagat R Kanwar

1 reference

9 December 2017

Haiquan Qiao

2

1 reference

9 December 2017

Hongchi Jiang

3

1 reference

9 December 2017

Xuting Zhi

4

1 reference

9 December 2017

Fengjun Liu

5

1 reference

9 December 2017

Jianli Wang

6

1 reference

9 December 2017

Meng Liu

7

1 reference

9 December 2017

Dianning Dong

8

1 reference

9 December 2017

Ruian Xu

10

1 reference

9 December 2017

Geoffrey W Krissansen

11

1 reference

9 December 2017

publication date

1 January 2005

1 reference

9 December 2017

1 reference

9 December 2017

volume

12

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

35-45

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700766

9 December 2017

exact match

0 references

cites work

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Angiostatin binds ATP synthase on the surface of human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin binds to the catalytic domain of matrix metalloproteinase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin is a potential inhibitor of Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Improving protein therapeutics with sustained-release formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Antiangiogenic gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Gene therapy strategies for tumor antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Non-viral gene delivery in skeletal muscle: a protein factory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Inflammatory responses following direct injection of plasmid DNA into skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Requirements for ICAM-1 immunogene therapy of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Endostatin action and intracellular signaling: beta-catenin as a potential target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

The promise of anti-angiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Secreted cathepsin L generates endostatin from collagen XVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

The body as a manufacturer of endostatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Intracellular Delivery of a Tat-eGFP Fusion Protein into Muscle Cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700766

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700766

1 reference

Dimensions Publication ID

9 December 2017

1030625302

0 references

1 reference